Johanna works in the development of routines and methods for the detection of drug-related problems in the WHO-ADR Database. She is involved in research projects related to signal detection and analysis, and also in the scientific aspects of WHO Drug Dictionary.

Johanna is currently working on a PhD with the main focus on development and detection of drug interactions.

E-mail: johanna.strandell@who-umc.org

Principal qualifications :

Master of Pharmaceutical Science, Uppsala University, 2003

Language skills: Swedish; English, French.

Papers :

Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? European Journal of Clinical Pharmacology. 2006 Jun; 62(6), 473-9.

Strandell J, Bate A, Lindquist M, Edwards I R, the SFINX group. Drug-drug interactions - a preventable patient safety issue? Br J Clin Pharmacol. 2008 Jan; 65(1):144-6.

Strandell J, Bate A, Hägg S, Edwards I R. Rhabdomyolysis a result of Azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009 Sep;68(3):427-34. 

Posters :

Strandell J, Kiuru A, Lindquist M. Linking Spontaneous Reports with pharmacogenetics. Basic & Clinical Pharmacology & Toxicology. Vol 97 supplement 1, 2005, 106

Yue Q-Y, Strandell J, Myrberg O. Concomitant use of glucosamine potentiates the effect of warfarin. Drug Safety. Vol 29, No. 10. 2006; 934 (41)

Strandell J, Bate A, Eiermann B, Lindquist M. Can WHO-Database of suspected ADRs be used to support existing information on pharmacokinetic drug interactions? Drug Safety. Vol 29, No.10. 2006; 933 (33)

Strandell J, Bate A, Lindquist M, Edwards I R. Drug Interaction Signal Detection in Spontaneous Reports. Pharmacoepidemiology and Drug Safety. Vol 16 supplement 2. 2007; S256 (540).